Mendus reports long-term progression-free survival associated with broad immune activation in high-risk ovarian cancer

What we doOur approachPipelineTechnologyPatient Stories
About usManagementBoardClinical Advisory BoardCareers
NewsroomPress releasesEvents
Investors

Back
Mendus reports long-term progression-free survival associated with broad immune activation in high-risk ovarian cancer
 8:00:00 AM

Keep reading
Mendus AB (publ) repurchases outstanding warrants from FenjaRead